Humoral antibody response in Arctic charr (Salvelinus alpinus) against Aeromonas salmonicida ssp. achromogenes following vaccination with a novel autogenous vaccine

Sigþóra Brynja Kristjánsdóttir, Heiðdís Smáradóttir, Rannveig Björnsdóttir*

*Corresponding author for this work

    Research output: Contribution to journalArticlepeer-review


    The bacterium Aeromonas salmonicida ssp. achromogenes (Asa) causes atypical furunculosis in salmonids that may lead to extensive financial losses in intensive fish farming. The commercially available vaccine commonly used against the ssp. achromogenes in the production of Arctic charr in Iceland has been developed for Atlantic salmon (Salmon salar) against the subspecies salmonicida which causes typical furunculosis, but it has insufficient efficacy in Arctic charr. In response to this, a novel vaccine against Asa in Arctic charr was developed in cooperation with Spanish vaccine company; HIPRA, and the antibody response of Arctic charr against Asa investigated using enzyme-linked immunosorbent assay. Fish used for testing were vaccinated using the novel, monovalent autogenous experimental vaccine and a commercially available vaccine Alpha Ject® 3000 developed for Atlantic salmon that was used as a comparison. The study was conducted in commercial production units where the fish were continually exposed to natural outbreaks of atypical furunculosis. Blood samples were collected from the fish prior to vaccination and thereafter at approximately ten-week intervals in each production unit throughout the production period until the fish reached harvesting size. Fish growth and mortality was recorded throughout the study. The results indicated that both vaccines induced antibody response in fish against Asa antigens and that antibody titers obtained during the first weeks following vaccination were maintained throughout the production period. However, significantly higher antibody titers were observed in fish vaccinated with the experimental novel vaccine and fish mortality was significantly lower in production units containing fish vaccinated with the novel vaccine in comparison to the Alpha Ject 3000® vaccine. These results suggest that the novel vaccine may be a promising candidate for protective immunity against atypical furunculosis caused by Asa in Arctic charr.

    Original languageEnglish
    Article number738676
    Publication statusPublished - 15 Dec 2022

    Bibliographical note

    Funding Information:
    The veterinary pharmaceutical company, HIPRA, in Spain is acknowledged for their financial support through providing the experimental autogenous vaccine used in the studies. The authors would also like to thank Eva Charlotte Halapi associate professor at the University of Akureyri for her assistance with visual exposition of the results and review of the manuscript's text, and Elísabet Eik Guðmundsdóttir project manager at Matís Food Research & Innovation for providing information on the classification of the bacterial isolate used in the novel experimental vaccine. The research was a part of a larger research project which was partially funded by the AVS Research & Innovation Fund of the Icelandic Government (Grant Number R-17-003 ).

    Publisher Copyright:
    © 2022 Elsevier B.V.

    Other keywords

    • Antibody response
    • Arctic charr
    • Growth
    • Survival
    • Vaccine efficiency


    Dive into the research topics of 'Humoral antibody response in Arctic charr (Salvelinus alpinus) against Aeromonas salmonicida ssp. achromogenes following vaccination with a novel autogenous vaccine'. Together they form a unique fingerprint.

    Cite this